Aug 2026· Apoptosis· Vol 31· 0 citations· 322 references
Medicine
TL;DR
Dual immunological identity of mutant p53 (mut-p53) functions as the context-dependent determinant of tumor immunogenicity and cancer immunotherapy outcome, underscoring its promise as both a biomarker and a therapeutic target in crafting next-generation precision cancer immunotherapy strategies.
Current approaches increasingly focus on combination strategies designed to simul taneously restore antigen presentation, improve immune -cell trafficking, overcome immunosuppression, reverse T -cell dysfunction, and increase tumor immunogenicity.
Ulykbek Daurenov, Ayaulym Sartaubai, Assiya Sherkhan et al.· International Scientific Uni...· 0 citations
Cutaneous melanoma (CM) is a highly immunogenic and therapeutically intricate solid tumor, exemplifying the interactions between tumors and the immune system. Despite the significant enhancement in survival rates for patients with advanced melanoma due to immune checkpoint inhibitors (ICIs), numerous patients either ex...
L. Ciuffreda, I. Falcone, C. Sorino et al.· Frontiers in Immunology· 0 citations
Cancer immunosurveillance is the immune‐mediated identification and elimination of malignant cells and is an essential mechanism to inhibit cancer growth. However, during cancer progression, tumors evolve various strategies to evade effective immune‐mediated eradication, a process termed tumor immune escape. Glioblasto...
S. MacDonald, Matthew Drill, Padmakrishnan C Jayakrishnan et al.· Immunology and Cell Biology· 0 citations
Tumor immunoediting is a dynamic process of interaction between the host immune system and tumor cells and encompasses three sequential phases: elimination, equilibrium, and escape. It plays a central regulatory role in melanoma initiation, progression, and therapeutic response. Currently, increasing attention has been...
Xiao-Jun Yan, Qian Zhang, Ze-Ping Chen et al.· Frontiers in Immunology· 0 citations
By integrating nanotechnology with immunotherapy, new opportunities arise to convert cold tumors into hot, immune-responsive phenotypes, thereby improving therapeutic efficacy and clinical outcomes.
M. Teiama, Asmaa Gohar, Mahmoud Amr et al.· Molecular Biomedicine· 0 citations
